ABstRAct
intRodUction
Vitamin D is an important hormone, historically considered a key requirement only for musculoskeletal development and function 1 . However, as the prevalence of low vitamin D status has increased dramatically in the general population of the United States 2 , its pleotropic effects have recently garnered significant attention 3, 4 . Growing recognition of the association between vitamin D insufficiency and increased risk of a significant number of major public health challenges has stimulated significant research on the topic 1, 5, 6 . Taken on aggregate, studiesthough varying in their specific outcomes -suggest that vitamin D supplementation may attenuate the risk of various diseases and may also reduce all-cause mortality [7] [8] [9] [10] [11] . In our current review of the literature, we will address some critical background information related to the measurement of vitamin D status, the appropriateness of 25-hydroxyvitamin D [25(OH)D] as a biomarker for disease, and the associations between vitamin D status as well as allcause mortality, cardiovascular disease, pulmonary ailments, diabetes mellitus, and cancer. We will also review the current evidence related to dosing of vitamin D supplements to achieve "therapeutic" levels of 25(OH)D.
MeAsURing VitAMin d LeVeLs
Vitamin D is a 27-carbon secosteroid, yet it is unlike most other hormones. Differences in source (endogenous vs. exogenous pre-hormone), extensive need for tissue modification (skin vs. liver vs. kidney), an active intermediary pro-hormone [25(OH)D], and a critical set of modulators (parathyroid hormone [PTH] , calcium, phosphorus, and fibroblast growth factor-23 ) add to the complexity of vitamin D regulation 12 . Taken together, these factors complicate the direct measurement of vitamin D, as well as which parameter would best reflect overall vitamin D status 13 .
Upon exposure to ultraviolet B irradiation, endogenous synthesis of vitamin D3 starts with a pho- 16 . This final step is rigidly controlled by the stimulus of PTH, inhibition by FGF-23, and circulating levels of calcium, phosphorus, and 1,25(OH)2D itself. These mechanisms are known to be highly efficient except during renal failure, when 1-α-hydroxylation is impaired despite high levels of PTH. Serum 25(OH)D levels are approximately 500-1000 times higher than 1,25(OH)2D levels, and both are predominantly protein bound in circulation. Indeed, only 0.03% of 25(OH)D is free, with close to 88% bound to DBP and the remainder to albumin 17 .
Serum 25(OH)D levels reflect overall vitamin D contact from diet and sunlight exposure 6 . In general, there is agreement that, under normal circumstances, the serum 25(OH)D level -free and bound, including both 25(OH)D3 and 25(OH)D2 -is the best indicator to define vitamin D status 3 . This is certainly unusual in the sense that a metabolite one step removed from the most biologically active form is used to assess adequacy. Nonetheless, 25(OH)D is the most abundant vitamin D metabolite and its relative stability in the systemic circulation makes it a good indicator of vitamin D stores in the general population. On the other hand, 1,25(OH)2D is present in picomolar concentrations and, because it is tightly regulated, the concentration can remain normal or even be elevated, despite evidence of deficiency 18 . Whereas, the half-life of serum 25(OH)D is generally 2-3 weeks, that of 1,25(OH)2D is only a few hours 17 . Furthermore, measurement of 1,25(OH) 2 D may be confounded by the greater technical difficulty in performing the assay (subject to greater error) and that conditions such as renal insufficiency or advanced aging reduce 1-α-hydroxylase activity, which is a major cause of low levels of 1,25(OH)2D independent of vitamin D stores 19 .
VitAMin d LeVeLs As A BioMARkeR
The role of 25(OH)D levels as a biomarker for disease is promising, but not uniformly accepted. Widespread utilization of thresholds to define disease risk has led to multiple issues from both a clinical and research perspective 20 . To date, there is no clear consensus about the optimal definitions of either vitamin D deficiency or insufficiency. While there is a strong interest to define the optimal vitamin D status for health, diverse cut points for serum levels of 25(OH)D have been suggested, ranging from 16 to 48 ng/ml 3, 15, 21 . This uncertainty likely originates from the lack of standardized vitamin D assay methodologies and differences in the measured functional endpoints used by various investigators 13 , which arise from the classic and non-classic effects of vitamin D.
The classic function of vitamin D is the control of extracellular calcium metabolism by regulating absorption in epithelia involved in calcium transport. Consequently, the traditional "low normal" level for serum 25(OH)D was 10 ng/mL, as this threshold had the advantage of high specificity for rickets and osteomalacia 18 . Since low vitamin D status stimulates PTH secretion to increase intestinal calcium absorption and bone resorption to maintain calcium balance, it has been proposed that vitamin D sufficiency be described as the concentration of 25(OH)D which achieves maximal PTH suppression 22 . In this regard, vitamin D sufficiency is defined by a serum 25(OH)D of ≥30 ng/mL 23 . Based on studies on fracture prevention, most The non-classic function of vitamin D includes regulation of cell proliferation and differentiation, regulation of hormone secretion, and the regulation of immune function 24 . These effects take place on a cellular level and are directly dependent on 25(OH)D levels. In fact, cells of the neuromuscular, cardiovascular, endocrine, and immune system express the vitamin D receptor (VDR) 25 . Furthermore, most of these cells express the 25(OH)D-1-α-hydroxylase, to produce 1,25(OH)2D for autocrine and paracrine use within the target cell itself 16 . The discovery of VDRs in activated immune cells has particularly stimulated research into the role of vitamin D in immune function 26 . It is now recognized that vitamin D plays a critical role in the regulation of the innate and the adaptive immune systems 27 . Therefore, vitamin D insufficiency is thought to be a mechanism underlying a range of inflammatory, autoimmune, and infective conditions 28, 29 . 1,25(OH)2D inhibits adaptive immunity by attenuating the proliferation and differentiation of both T and B lymphocytes, which is thought to ameliorate the severity of inflammatory and autoimmune diseases 30 . In contrast to its inhibitory role in adaptive immunity, 1,25(OD)2D is a potent activator of the innate immune system 31 . Innate immunity represents the first line of defense against microbial invasion and constitutes both epithelial and mucosal cells, as well as polymorphonuclear leukocytes, monocytes, and macrophages 25 . The central mechanism underlying microbial eradication is the activation of toll like receptors in the host cell, which induces formation of potent antimicrobial peptides such as cathelicidin 32 . Macrophages and epithelial cells respond to both circulating and local 1,25(OH)2D synthesized by 1-α-hydroxylase activity on 25(OH)D. Recent evidence indicates that a positive correlation exists between cathelicidin concentrations and 25(OH)D levels ≤32 ng/ mL 33 . This suggests that serum levels of 25(OH) D >30 ng/mL might be necessary for vitamin D to optimally exert its non-classical effects. 
AssociAtions BetWeen VitAMin d And diseAse

Methods
Vitamin D and All-cause Mortality
On prospective evaluation of more that 3000 patients, 25(OH)D levels ≤20 ng/mL were associated with an almost 2-fold increased risk of all-cause mortality compared to patients with 25(OH)D levels >30 ng/mL 34 . Moreover, retrospective data analysis from more than 13,000 adults in the National Health and Nutrition Examination Survey (NHANES) III suggested that individuals with 25(OH)D levels <17.8 ng/mL were likely to have a 26% increased risk of mortality compared to individuals with 25(OH)D >32.1 ng/mL 35 . Another study on the same NHANES III data observed a potential 5% reduction in the risk of all-cause mortality for every 4ng/mL increase in 25(OH)D levels between 0 ng/mL (extrapolation) and 48 ng/ mL 36 . All-cause mortality in subjects who participated in randomized trials testing the impact of vitamin D supplementation on any health condition have also been examined. In one report of 18 independent randomized controlled trials (RCTs) 10 , daily vitamin D supplementation (ergocalciferol or cholecalciferol) in usual doses (400-800 IU) was associated with a 7% decrease in mortality risk when compared to controls. In a larger metaanalysis of 50 independent RCTs 11 , daily vitamin D supplementation (cholecalciferol, ergocalciferol,
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alfacalcidiol, or calcitriol) in usual doses was associated with a 3% decrease in mortality risk when compared to controls. In a subgroup analysis of subjects who received cholecalciferol, a potential 6% reduction in mortality risk was observed. Consequently, intake of ordinary doses of vitamin D supplements seem to be associated with decreases in total mortality rates. In a separate, large study, with approximately 11,000 patients, 25(OH) D levels <30 ng/mL were associated with a greater than 1.5-fold increased risk of all-cause mortality when compared to patients with levels ≥30 ng/ mL 7 . Vitamin D supplementation (between 1000 IU/day to 50,000 IU biweekly) on the other hand, was associated with a 60% reduction in the risk of all-cause mortality. Furthermore, it is estimated that if global 25(OH)D levels increased from 21.6 ng/ mL to 44 ng/mL, reduction in the risk of all-cause mortality may range from 7.6% for African females to 17.3% for European females 37 . Expected reductions for males are on average 0.6% lower than for females. The estimated increase in life expectancy could be 2 years across all geographical regions. Despite some good evidence to suggest an association between 25(OHD levels, supplementation, and all-cause mortality, future large-scale RCTs using standardized measurement and supplementation protocols will be key to understanding the nature of the relationship between vitamin D and mortality.
Cardiovascular Disease
In a moderately-sized prospective study with 239 patients undergoing coronary angiography, 25(OH) D levels were shown to have a significant inverse association with the severity of coronary artery stenosis 38 . As such, a large retrospective analysis from the Framingham offspring study, which included more than 1700 participants, confirmed the association between vitamin D levels and cardiovascular events 39 . Individuals with 25(OH)D levels <15 ng/ mL had a potential 62% greater risk of incident cardiovascular events when compared to individuals with 25(OH)D levels ≥15 ng/mL. A potential 2-fold increase in the risk of incident cardiovascular events was observed in hypertensive individuals in this cohort. Similarly, a potential 3-fold increase in the risk of incident myocardial infarction (MI) was observed in hypertensive patients in a small retrospective study of 139 patients admitted to the hospital for acute coronary syndrome, where patients with 25(OH)D levels >14 ng/mL were compared to patients with levels ≤14 ng/mL 40 . Furthermore, with over 3000 participants, Dobnig et al. prospectively demonstrated that 25(OH)D levels ≤20 ng/ mL were associated with an approximate 2-fold increased risk of cardiovascular mortality compared to patients with 25(OH)D levels >30 ng/mL (34) . Moreover, in a much larger retrospective data analysis from more than 13,000 adults in NHANES III, individuals with 25(OH)D levels <10 ng/mL had a potential 1.5-fold increased risk of cardiovascular mortality compared to individuals with 25(OH)D ≥40 ng/mL 36 . Participants with 25(OH)D levels <21 ng/mL had a potential 30% greater risk of hypertension and almost 50% greater risk of hypertriglyceridemia when compared to participants with 25(OH) D ≥37 ng/mL. And although a recent prospective study of over 2000 participants free of cardiovascular disease at baseline demonstrated no association between 25(OH)D levels and overall cardiovascular mortality 41 , a potential 25% increase in the risk of incident myocardial infarction (MI) was observed for every 10 ng/mL decrement in 25(OH) D levels ≤30 ng/mL. In hypertensive patients with type 2 diabetes mellitus, a single dose of 100,000 IU ergocalciferol (n=17) was associated with a 14 mmHg drop in systolic pressure when compared to the placebo group (n=17) 42 . And in another small randomized clinical trial of 77 women, treatment with 1000 IU of cholecalciferol over 12 weeks was associated with significant improvements in high-density lipoprotein, apolipoprotein A1, and low-density lipoprotein : apolipoprotein B100 ratio when compared to a placebo group 43 . To date, investigations related to vitamin D-related gene polymorphisms have not resulted in convincing association studies [44] [45] [46] . Furthermore, despite significant evidence that suggests hypovitaminosis D may be associated with poor cardiovascular outcomes, there remains a great need for high-quality RCTs to investigate the effect of vitamin D supplementation on cardiovascular-specific morbidity and mortality.
Respiratory Disease
The relationship between vitamin D status and tuberculosis (TB) has been studied more extensively than most other pulmonary diseases. A recent meta-analysis of 7 studies estimated that individuVitamin D and Major Chronic Illness als with active TB had a 70% likelihood of significantly lower 25(OH)D levels when compared to similar non-TB infected individuals 47 . In a RCT of 192 patients exposed to TB, subjects treated with a single dose of 100,000 IU of vitamin D2 had a significantly enhanced anti-mycobacterial immune response compared to controls 48 . Similarly, pulmonary TB patients treated with conventional therapy plus 10,000 IU of daily cholecalciferol (n=34) for 6 weeks had a significantly higher sputum conversion rate compared to TB patients treated with conventional therapy alone (n=33) 49 . Conversely, a similar trial of 126 patients reported no difference in the global sputum conversion rate when patients received 100,000 IU of cholecalciferol (or placebo) on days 14, 28, and 42 of conventional therapy 50 . Sputum conversion rate was, however, significantly higher in vitamin D supplemented patients with the tt genotype in TaqI of the VDR gene.
Vitamin D status may also affect patients with asthma. Prospective analysis of 54 adults with diagnosed asthma demonstrated a significant inverse relationship between 25(OH)D levels and airway hyper-responsiveness as well as FEV1 51 . In addition, 25(OH)D levels were directly related to the response to glucocorticoid therapy. However, these results could not be duplicated in larger studies in adults 52, 53 , while others demonstrated a stronger association in children 54, 55 . And although a direct association between vitamin D status and risk of asthma has not been reported in large cohorts, a significant association between variations in the VDR gene and asthma has been observed 56, 57 , suggesting are role for genetic susceptibility to play a role in the observed associations in smaller cohort studies.
Seasonal variations in influenza and pneumococcal community acquired pneumonia suggest that vitamin D may play an important role in disease risk 58, 59 . In a prospective analysis of 112 patients hospitalized for community acquired pneumonia, 25(OH)D levels <12 ng/mL upon admission were associated with more than 13-fold increased risk of 30-day mortality when compared to similar patients with 25(OH)D levels ≥12 ng/mL 60 . Furthermore, prospective analysis of 198 healthy adults, during a single fall and winter season, subjects with 25(OH) D levels <38 ng/mL had a potential 2-fold increased risk of viral respiratory illness when compared to subjects with 25(OH)D levels ≥38 ng/mL 61 .
In another prospective study of 756 young males followed over a 6 month period, 25(OH)D levels <16 ng/mL were associated with a 63% increased risk of more days missed from work due to upper respiratory illness (URI) when compared to 25(OH) D levels ≥16 ng/mL 62 . Retrospective analysis of the NHANES III data in over 18,000 participants demonstrated that 25(OH)D levels <10 ng/mL were associated with a 36% increased risk of recent URI, while 25(OH)D levels ≥10 to <30 ng/mL were associated with a 24% increased risk, when compared to participants with 25(OH)D levels ≥30 ng/mL 63 . Similarly, in a retrospective analysis of 6789 adult subjects from the Nationwide 1958 British Birth Cohort, when the reference group was set as participants with 25(OH)D levels <10 ng/mL, each 4 ng/ mL increase in 25(OH)D levels was associated with a 7% reduction in risk of URI 64 . A RCT of 164 men who received 400 IU of cholecalciferol (or placebo) over a 6-month period demonstrated a potential 30% reduction in the risk of missed working days from URIs 9 . Similarly, in a post hoc analysis of 208 women participating in a 3-year vitamin D trial for osteoporosis, URIs were reported by a significantly less number of participants from the treatment group (up to 2000 IU daily) vs. controls 65 .
A positive correlation between 25(OH)D levels and lung function (forced expired volume in one minute -FEV1 -and/or forced vital capacity -FVC) has been observed in moderate to large-sized studies in adult CF patients [66] [67] [68] and in subjects with chronic obstructive pulmonary disease (COPD) [69] [70] [71] . In a prospective study of 414 patients with COPD, 25(OH)D levels <20 ng/mL were significantly associated with greater severity of disease 71 . Moreover, the TT genotype in GC of the DBP gene was shown to be associated with a 2-fold increase in risk for COPD. Another cohort analysis of 79 COPD patients demonstrated a positive correlation between 25(OH)D and exercise capacity 70 . Nonetheless, a RCT of 182 COPD patients receiving 100,000 IU cholecalciferol (or placebo) every 4 weeks over a period of one year did not show a global difference in rates of exacerbation, hospitalization, quality of life, or death 72 . However, in the subset of patients with 25(OH)D levels <10 ng/mL (n=30) an almost 40% potential reduction in risk of COPD exacerbations was observed in association with vitamin D supplementation. Overall, these clinical associa-
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tions and early trials suggest that vitamin D may be beneficial in patients with various pulmonary diseases, but more importantly highlight the urgent need for further well-designed, high-quality, RCTs.
Diabetes Mellitus
Epidemiologic data suggests a link between exposure to vitamin D early in life and the development of type 1 diabetes mellitus (DM). A retrospective analysis of over 10,000 adults followed since birth (for approximately 31 years) demonstrated an potential 80% reduction in the risk of developing type 1 DM in individuals who regularly consumed a 2000 IU vitamin D supplement vs. those who consumed lower doses 73 . These findings were reproduced in a meta-analysis of 5 case-controlled studies, which concluded that a 30% reduction in risk for type 1 DM later in life may be associated with regular vitamin D supplementation in infancy. Of note, a dose-response effect was observed, whereby patients taking higher doses of supplements appeared to have a lower risk of disease 74 . Moreover, regression analysis of national registry data from Finland revealed an inverse association between decreasing public health department recommendations for daily vitamin D supplementation over 40 years (1965-2005) and the incidence of type 1 DM during the same time period 75 . Furthermore, a metaanalysis of 57 case-controlled studies demonstrated that the presence of the B allele (BB or Bb) in Bsml of the VDR gene was associated with a 30% greater risk of type 1 DM 76 . However, subgroup analysis revealed the effect was predominantly in patients of Asian decent (where the risk appeared to be almost 2-fold).
The risk of developing type 2 DM may also be related to vitamin D status. On multiple regression analysis of 126 glucose-tolerant adults, a positive association was observed between 25(OH)D levels and insulin sensitivity 77 . In the same study, not only was there a negative association between 25(OH)D levels and observed plasma glucose during oralglucose-tolerance testing, but also in subjects with baseline 25(OH)D levels <20 ng/mL there was a higher prevalence of components of the metabolic syndrome. Similar associations between 25(OH)D levels, β-cell function, and insulin sensitivity were reproduced in a more recent study involving 150 healthy, glucose-tolerant subjects 78 . Although metaanalysis of 4 observational studies failed to show an overall association between 25(OH)D levels and risk of type 2 DM 79 , after excluding data from non-Hispanic blacks, 25(OH)D levels between 25-38 ng/mL were associated with a 65% reduction in the risk of type 2 DM compared to subjects with 25(OH)D levels between 10-23 ng/mL. In a more recent meta-analysis of 11 prospective studies, 25(OH)D levels >32 ng/mL were associated with a 40% lower risk of type 2 DM compared to 25(OH) D levels <19.6 ng/mL 80 79 . A combined daily intake of >1,200 mg calcium and >800 IU vitamin D was associated with a 33% lower risk of type 2 DM when compared with an intake of <600 mg calcium and 400 IU of vitamin D. Despite a number of small, yet targeted studies to examine the association between vitamin D-related gene polymorphisms and type 2 DM, convincing data is yet to be reported [82] [83] [84] [85] [86] . Taken all together, associations between 25(OH)D and type 1 as well as type DM are undeniable. Yet, there remains a great need for well-designed, high-quality RCTs to determine whether vitamin D supplementation can improve outcomes in type 1 and/or type 2 DM.
Cancer
Associations between 25(OH)D and outcomes in cancer are likely related to the actions of vitamin D on cell growth and differentiation 87 . Predictions based on cohort data analysis of over 1000 men from the Health Professionals Follow-Up study suggested that over a range of baseline 25(OH)D levels of 9 to 36 ng/mL, a 10 ng/mL increment in 25(OH)D levels would be associated with a 17% reduction in the risk of total cancer incidence and 29% reduction in the risk of total cancer-related Vitamin D and Major Chronic Illness mortality 88 . In a subset analysis of only digestive system cancers, the same 10 ng/mL increment in 25(OH)D levels was estimated to result in a 43% reduction in the risk of cancer and a 45% reduction in the risk of cancer-related mortality. Nonetheless, analysis of the NHANES III data from over 16,000 participants failed to demonstrate a relationship between 25(OH)D and total cancer mortality, except in patients with colorectal cancer 89 .
In the colorectal cancer subset from NHANES III, 25(OH)D levels ≥32 ng/mL were associated with a 72% reduction in risk of colorectal cancer-related mortality compared to 25(OH)D levels <20 ng/ mL 89 . A meta-analysis of 9 other studies also demonstrated that over a range of clinically applicable values for 25(OH)D, each 10 ng/mL increment in 25(OH)D levels is associated with a 7% reduction in the risk of colorectal cancer 90 . Moreover, a meta-analysis of 5 nested case-control studies demonstrated that 25(OH)D levels ≥33 ng/mL was associated with a 50% reduction in risk of colorectal cancer compared to 25(OH)D levels ≥12 ng/mL 91 . In a more comprehensive meta-analysis of 10 prospective studies, each 100 IU increment in dietary vitamin D consumption (over a range of 39-719 IU) was associated with a 5% reduction in the risk of colorectal cancer 92 . And although pooled data from 2 studies also demonstrated that each 100 IU increment in vitamin D supplementation (over a range of 0-600 IU) was associated with a 7% reduction in the risk of colorectal cancer, a significant inverse association between total vitamin D consumption and colorectal cancer risk could not be detected 92 . Genetic analysis has not demonstrated an association between most vitamin D-related polymorphisms and the risk of colorectal cancer, expect in a single meta-analysis of 8 studies, where the BB genotype in Bsml of the VDR gene was associated with a 40% reduction in the risk of colorectal cancer compared to the bb genotype 92 . However, another meta-analysis of 5 case-controlled studies failed to demonstrate an association between risk of colorectal cancer and polymorphisms in the VDR genes Fokl and Bsml 90 .
In a large prospective analysis of over 30,000 participants from the Women's Health Study, followed for 10 years, daily consumption of calcium ≥1366 mg and vitamin D ≥548 IU amongst premenopausal women was associated with a 40% reduction in the risk of breast cancer compared to daily consumption of calcium <617 mg and vitamin D <142 IU 93 . A separate RCT in postmenopausal women found significant overall cancer-related benefit associated with calcium and vitamin D consumption 8 . In an analysis of over 1100 postmenopausal women, followed over 4 years, daily consumption of 1500 mg calcium and 1100 IU cholecalciferol was associated with a 60% reduction in the risk of all cancers compared to placebo. Meta-regression analysis of 9 studies found that a 20 ng/mL increase in 25(OH)D over a clinically valid range of baseline values was associated with a 20% reduction in the risk of breast cancer 94 . Similarly, another meta-regression analysis of 10 studies confirmed that a 10 ng/mL increase in 25(OH)D over a clinically valid range of baseline values was associated with a 10% reduction in the risk of breast cancer 95 . In contrast to these findings, a RCT of over 5000 participants (85% female) over a 3-year period did not find a difference in mortality, vascular disease, cancer mortality, or cancer incidence between participants randomized to daily calcium 1000 mg and vitamin D 800 IU vs. placebo 87 . Genetic studies on the association between common vitamin D-related polymorphisms and breast cancer risk have resulted in conflicted reports 96 . While no association was appreciated in women of Chinese decent 97 , pooled data from 6 prospective studies demonstrate that the ff genotype in Fokl of the VDR gene is associated with a 16% increased risk of breast cancer compared to the FF genotype 98 . This association was replicated in a larger meta-analysis of 21case-controlled studies, which also suggested that the results were mostly significant in subjects of European decent 99 . A more recent retrospective analysis of over 1,700 patients and over 1,800 controls in the Canadian province of Ontario demonstrated that the ff genotype in Fokl of the VDR gene is associated with a 30% reduction in the risk of breast cancer 100 . Conversely, the BB genotype in Bsml of the VDR gene was found to be associated with a 25% reduction in risk of advanced breast cancer compared to the bb genotype in one meta-analysis 98 , but this result was not replicated in a larger meta-analysis 99 .
To date, all meta-analyses related to vitamin D and prostate cancer have been unable to detect an association 95, [101] [102] [103] . As such, existing data supports a strong association between vitamin D and colorectal cancer and a clinically relevant association be-
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tween vitamin D and breast cancer (the heterogeneity of which may be explained by genetic studies). However, more focused, high-quality RCTs are needed to determine whether vitamin D supplementation can improve outcomes.
PUtting it togetheR foR cLinicAL PRActice
Based on the evidence reviewed, 25(OH)D levels ≥20 ng/mL appear to be associated with desirable health outcomes. However, it would appear that health benefits can also be appreciated with 25(OH) D levels ≥30 ng/mL. It is also worth noting that even today, equatorial inhabitants with traditional lifestyles have 25(OH)D levels around 46 ng/mL, which may provide us with valuable information regarding optimal vitamin D status from an evolutionary perspective 104 . A target 25(OH)D level of 30-50 ng/mL is therefore consistent with guidelines from scientific authorities, grass-roots organizations, and nature 3, 4, 15, 104 .
Few recent studies have addressed the issue of optimal daily supplementation regimens. In a small, randomized study of 30 healthy, young subjects, doses of 200 IU and 4000 IU cholecalciferol were compared to placebo over a period of 28 days during winter 105 . The overall mean baseline 25(OH) D level in this group was 32.2 ng/mL. No significant changes in 25(OH)D levels were observed in the placebo and 200 IU cholecalcifrol groups. However, significant elevations in 25(OH)D levels were apparent on weekly assessments in the 4000 IU cholecalciferol group with a mean elevation of approximately 17 ng/mL at the end of the study, compared to baseline. The effectiveness of a daily 4000 IU cholecalciferol dose was also reported in 2 earlier clinical trials 106, 107 . In a conceptually similar study, 30 slightly older, healthy patients with 25(OH)D levels ≤20 ng/mL, were randomized to receive either 2000 or 5000 IU cholecalciferol over a 3 month period 108 . The 2000 IU group, which had a mean baseline 25(OH)D level of 16.5 ng/mL, experienced a mean increase of 14 ng/mL. The 5000 IU group, which had a mean baseline 25(OH)D level of 14.3 ng/mL, experienced a mean increase of 32 ng/mL. 45% vs. 93% of subjects achieved 25(OH)D levels >30 ng/mL in the 2000 IU vs. 5000 IU cholecalciferol groups. In a study involving 67 healthy males, daily cholecalciferol doses of 1000 IU, 5000 IU, and 10,000 IU were compared to placebo over a period of 20 weeks 109 . Daily 1000 IU cholecalciferol was associated with a mean elevation in 25(OH)D levels of 4.8 ng/mL at steady state, which was achieved at approximately 30 days; a daily dose of 5000 IU cholecalciferol was associated with a mean elevation in 25(OH)D levels of 36.6 ng/mL at steady state, which was achieved at approximately 100 days; and finally, a daily dose of 10,000 IU cholecalciferol was associated with a mean elevation in 25(OH)D levels of 63.5 ng/mL at steady state, which was achieved at approximately 120 days. Though study compliance was acceptable in all of studies, adherence to a daily schedule may not be a realistic expectation in the general population.
Based on such concerns, there is a growing trend in the literature to evaluate the effect of megabolus doses of vitamin D supplements on 25(OH) D levels. The effect of a single 100,000 IU cholecalciferol dose in 30 healthy subjects with a mean baseline 25(OH)D level of 24 ng/mL was shown to produce a mean peak rise of 15 ng/mL at about 7 days post-supplementation 110 . 25(OH) D levels dropped to <32 ng/mL by day 84 postsupplementation. The tolerability of such a dose was demonstrated in an earlier study, where 2686 elderly participants took either 100,000 IU cholecalciferol or placebo every 4 months for a duration of 5 years 111 . In a more detailed study design, involving 224 women diagnosed with breast cancer, 3 different supplementation regimens based on pre-study 25(OH)D levels were compared over a period of 8-16 weeks 112 . Women with 25(OH)D ≥32 ng/mL were prescribed no supplementation, while those with 25(OH)D 25 to <32 ng/mL were prescribed daily 1000 IU cholecalciferol (low dose supplementation group). The high dose supplementation group included women with 25(OH)D 15 to <25 ng/mL, who were prescribed weekly 50,000 IU cholecalciferol and women with 25(OH)D <15 ng/mL, who were prescribed weekly 100,000 IU cholecalciferol. Mean change in 25(OH)D levels were 3.1 ng/mL, 9.4 ng/mL, and 24.3 ng/mL in the no supplementation, low dose supplementation, and high dose supplementation groups, respectively. With continued concerns over patient compliance and the need for frequent checks, an annual dose Vitamin D and Major Chronic Illness of 500,000 IU cholecalciferol was administered to 102 elderly, community-dwelling females for 3-5 years 113 . Mean 25(OH)D levels was 28 ng/ mL immediately before the second dose. Mean 1-month and median 3-month post supplementation 25(OH)D levels were 49 ng/mL and 36 ng/mL, respectively. Similarly, 12 home-dwelling, elderly subjects were given a single oral dose of 600,000 IU cholecalciferol 114 . Mean baseline 25(OH)D was 21.7 ng/mL with a mean peak increment to 67.1 ng/ mL (Δ 45.4 ng/mL) on day 3 post-supplementation. Mean 25(OH)D levels were down to 35.2 ng/mL by day 90 post-supplementation.
It is important to note that none of the patients in the daily regimen or bolus dose studies discussed above experienced vitamin D toxicity, despite many patients achieving 25(OH)D levels above the IOM's "safe" threshold of 50 ng/mL 3 . In fact, the majority of published reports suggest that even early signs and symptoms of vitamin D toxicity (hypercalcuria and hypercalcemia) do not appear until 25(OH) D levels exceed 200 ng/mL [115] [116] [117] [118] . Application of a conservative "uncertainty factor" of 2 119 would indicate that an upper threshold for 25(OH)D levels may be 100 ng/mL 117 . The maximum daily dose of cholecalciferol is also debatable, since reports of vitamin D toxicity have only been reported with doses >40,000 IU per day 119, 120 . The reported maximum tolerable dose of cholecalciferol, used over an extended period of time, is nonetheless 50,000 IU 109, 121 . Application of a conservative "safety factor" of 5 119 would indicate that an upper threshold for daily cholecalciferol dosing may be 10,000 IU 122 . Certainly, the extended use of such a dose has been demonstrated to be safe 109, 121 and is estimated to be equivalent to the natural production of 25(OH)D upon liberal skin exposure to sunlight 120, 123 .
concLUsion
Association studies point to a clinically significant relationship between 25(OH)D levels and the risk of all-cause mortality, cardiovascular disease, pulmonary ailments, diabetes mellitus, and cancer. Yet, RCTs to date, limited by small sample sizes, heterogeneous dosing schedules, and varying study end-points, have been less persuasive. High quality RCTs are needed to determine: 1) optimal 25(OH) D levels for overall health; 2) whether vitamin D supplementation can improve outcomes; and 3) how to dose supplements in order to achieve optimal 25(OH)D levels.
Based on existing evidence, a target 25(OH)D range of 30-50 ng/mL would most likely optimize potential health-related benefits of vitamin D and minimize the potential for harm. Although a maximum safe level for 25(OH)D may be 100 ng/ mL, additional health benefits with levels between 50-100 ng/mL are not apparent. As such, depending on baseline levels, daily cholecalciferol dosing of either 5000 IU or 10,000 IU appears to be safe and effective in restoring 25(OH)D levels to a therapeutic range. Bolus doses between 50,000 and 600,000 IU have been studied in the general population and are thought to be safe (although studies with doses >150,000 IU have generally involved a small number of subjects). The selection of a bolus regimen should take into consideration the desired elevation in 25(OH)D and frequency of dosing. Since 25(OH) D levels peak between days 3 and 7 following a bolus (depending on the size of the bolus dose), this provide a "monitoring window" to assess either adequacy of supplementation or potential for toxicity. There is currently insufficient evidence to provide guidance regarding a combined bolus and daily supplementation regimen. However, this may provide a reasonable approach when the goal is to rapidly restore and then maintain 25(OH)D levels in severely deficient patients. Any intensive vitamin D repletion program should, of course, be considered in the context of individual patient co-morbidities and desired outcomes. 
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